Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Joint Authors
Palla, Ilaria
Kheiraoui, Flavia
de Waure, Chiara
Iaccarino, Luca
La Torre, Giuseppe
Nicolotti, Nicola
Gliubizzi, Daniela
Ricciardi, Gualtiero
Capizzi, Silvio
Pierotti, Francesca
Veneziano, Maria Assunta
Gualano, Maria Rosaria
Sferrazza, Antonella
Turchetti, Giuseppe
Di Nardo, Francesco
Cadeddu, Chiara
Porcasi, Rolando
Doria, Andrea
Pippo, Lara
Di Pietro, Maria Luisa
Specchia, Maria Lucia
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-08-17
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Objective.
Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics.
Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease.
This paper summarizes a health technology assessment performed in Italy.
Methods.
SLE epidemiology and burden were assessed using the best published international and national evidences and efficacy and safety of belimumab were synthesized using clinical data.
A cost-effectiveness analysis was performed by a lifetime microsimulation model comparing belimumab to standard of care (SoC).
Organizational and ethical implications were discussed.
Results.
Literature review showed that SLE affects 47 per 100,000 people for a total of 28,500 patients in Italy, 50% of whom are affected by active form of the disease despite SoC.
These patients, if autoantibodies and anti-dsDNA positive with low complement, are eligible for belimumab.
SLE determines work disability and a 2–5-fold increase in mortality.
Belimumab with SoC may prevent 4,742 flares in three years being cost-effective with an incremental cost-effectiveness ratio of €32,859 per quality adjusted life year gained.
From the organizational perspective, the development of clear and comprehensive clinical pathways is crucial.
Conclusions.
The assessment supports the use of belimumab into the SLE treatment paradigm in Italy.
American Psychological Association (APA)
Specchia, Maria Lucia& de Waure, Chiara& Gualano, Maria Rosaria& Doria, Andrea& Turchetti, Giuseppe& Pippo, Lara…[et al.]. 2014. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-491904
Modern Language Association (MLA)
Specchia, Maria Lucia…[et al.]. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-491904
American Medical Association (AMA)
Specchia, Maria Lucia& de Waure, Chiara& Gualano, Maria Rosaria& Doria, Andrea& Turchetti, Giuseppe& Pippo, Lara…[et al.]. Health Technology Assessment of Belimumab : A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-491904
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-491904